Mieloma Múltiplo - Resenha / Multiple Myeloma - Review
RBM rev. bras. med
;
69(1,esp)jan. 2012.
Article
in Portuguese
| LILACS
| ID: lil-639227
ABSTRACT
Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma combination regimens; however, the doses employed are often poorly tolerated, especially in patients with concurrent comorbid conditions. We hypothesized that a steroid-independent combination regimen could be developed without significant compromise of efficacy. The availability of such a regimen will be important for patients whose concurrent ailments make them poor candidates for steroid containing anti-myeloma regimens. A phase II single institute, non-randomized clinical trial was conducted to investigate a novel steroid-free three-drug combination of bortezomib (V), pegylated liposomal doxorubicin (D), and thalidomide (T), the VDT regimen. Forty-three newly diagnosed multiple myeloma patients requiring treatment were enrolled on this study. The overall response rate and complete response (CR) + near complete response (nCR) rate was 78% and 35%, respectively. Median time to progression was 29.5 months. Fatigue, rash, neuropathy, constipation and infections were the most common side effects. We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens.
RESUMO
O mieloma mútliplo representa a segunda neoplasia hematológica mais frequente, cuja cura ainda permanece distante. A maioria dos esquemas para tratamento utiliza doses elevadas de corticoides que são altamente eficazes no controle da doença. No entanto, trata-se de doença que acomete preferencialmente idosos população sujeita a apresentar comorbidades que limitam o uso dos esteroides.Esse estudo avalia um esquema de tratamento que utiliza drogas sabidamente efetivas contra o mieloma bortezomibe, doxorrubicina lipossomal e talidomida porém sem o uso associado de corticoide. Apesar de se tratar de estudo com número reduzido de pacientes apenas 40 avaliados , a taxa de resposta global (78%) e as taxas de resposta completa e quase completa (35%), além da média de tempo livre de progressão da doença (29,5 meses), são consideráveis. Um ponto a ser destacado é que a associação de duas drogas potencialmente neurotóxicas bortezomibe e talidomida não aumentou significativamente a incidência de neuropatia.
Search on Google
Index:
LILACS (Americas)
Main subject:
Adrenal Cortex Hormones
/
Multiple Myeloma
Type of study:
Controlled clinical trial
/
Evaluation studies
Limits:
Humans
Language:
Portuguese
Journal:
RBM rev. bras. med
Journal subject:
Medicine
Year:
2012
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Faculdade de Medicina do ABC/BR
Similar
MEDLINE
...
LILACS
LIS